The experimental development of bioreductive drugs and their role in cancer therapy P. WorkmanI. J. Stratford OriginalPaper Pages: 73 - 82
DT-diaphorase in activation and detoxification of quinones David RossDavid SiegelNeil W. Gibson OriginalPaper Pages: 83 - 101
NAD(P)H:Quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues Martin BelinskyAnil K. Jaiswal OriginalPaper Pages: 103 - 117
Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent Laurence H. Patterson OriginalPaper Pages: 119 - 134
Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs) William A. DennyWilliam R. Wilson OriginalPaper Pages: 135 - 151
Cellular approaches to bioreductive drug mechanisms A. Michael RauthRaymond S. MarshallBonnie L. Kuehl OriginalPaper Pages: 153 - 164
Cellular pharmacology of quinone bioreductive alkylating agents Sara RockwellAlan C. SartorelliKatherine A. Kennedy OriginalPaper Pages: 165 - 176
Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference toin vivo methods of evaluation Jane C. M. Bremner OriginalPaper Pages: 177 - 193
The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT) Richard J. KnoxFrank FriedlosMarion P. Boland OriginalPaper Pages: 195 - 212